menu
    • menu

    Company profile for Airna

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+. AIRNA is advancing its first therapeutic program, a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitrypsin defici...
    AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+. AIRNA is advancing its first therapeutic program, a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), as well as a pipeline of therapeutic candidates to address multiple diseases with high unmet needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AirnaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge, MA
    Telephone
    Telephone
    +1 6179357092
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://airna.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/airna-bio/?viewAsMember=true
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AIRNA Data Supports RNA Editing for AATD at 28th ASGCT Meeting
    AIRNA Data Supports RNA Editing for AATD at 28th ASGCT Meeting

    13 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250513688828/en/AIRNA-Presents-Data-Supporting-RNA-Editing-Approach-for-Alpha-1-Antitrypsin-Deficiency-AATD-at-28th-ASGCT-Annual-Meeting

    BUSINESSWIRE
    13 May 2025
    Share Share
    AIRNA Appoints Jacob Elkins Chief Medical Officer
    AIRNA Appoints Jacob Elkins Chief Medical Officer

    16 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250416772196/en/AIRNA-Appoints-Jacob-Elkins-Chief-Medical-Officer

    BUSINESSWIRE
    16 Apr 2025
    Share Share
    AIRNA Raises $155M Series B to Fund Alpha-1 Antitrypsin Deficiency
    AIRNA Raises $155M Series B to Fund Alpha-1 Antitrypsin Deficiency

    01 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250401473885/en/AIRNA-Raises-Oversubscribed-%24155-Million-Series-B-Financing-to-Fund-Phase-12-Clinical-Trial-for-Alpha-1-Antitrypsin-Deficiency-and-Future-Pipeline

    BUSINESSWIRE
    01 Apr 2025
    Share Share
    AIRNA Appoints Matthew Hawryluk as Chief Business Officer
    AIRNA Appoints Matthew Hawryluk as Chief Business Officer

    30 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250130051740/en

    BUSINESSWIRE
    30 Jan 2025
    Share Share
    AIRNA Launches to Develop New Class of RNA Editing Therapeutics
    AIRNA Launches to Develop New Class of RNA Editing Therapeutics

    19 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230919739321/en

    BUSINESSWIRE
    19 Sep 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search